US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs

Renaissance Capital2022-02-05

The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

748

Report

Comment（44）

frusty
·2022-02-06
Ok
Reply
2
Report
Bspn
·2022-02-06
Ok
Reply
1
Report
BKT
·2022-02-05
Good. Pls like thanks.
Reply
2
Report
AngelAw
·2022-02-05
Good
Reply
1
Report
cubinvestor
·2022-02-05
Great [Strong]
Reply
2
Report
Goodmeng
·2022-02-05
Nice
Reply
1
Report
Jess261
·2022-02-05
Okay
Reply
1
Report
Gladys8jk
·2022-02-05
Ok
Reply
3
Report
Desoupie
·2022-02-05
Like pls [Bless]
Reply
6
Report
Success88
·2022-02-05
Great
Reply
4
Report
pushpa
·2022-02-05
how edge @___霞儿____sxeocbshh jgbenz
Reply
2
Report
Venus888
·2022-02-05
Pls like. Thanks
Reply
3
Report
ping23
·2022-02-05
pls like
Reply
6
Report
haircut
·2022-02-05
More biotech IPO?
Reply
4
Report
SSSG
·2022-02-05
Ok
Reply
4
Report
ToTheM00N
·2022-02-05
Pls like
Reply
4
Report
Vicholes
·2022-02-05
[smile]
Reply
4
Report
Jameslim29
·2022-02-05
Nice
Reply
6
Report
Gerinit
·2022-02-05
👍
Reply
2
Report
YauDK
·2022-02-05
Oh ye ye
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1197042929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-05 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197042929","market":"us","top_or_hot":-1,"title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","media":"Renaissance Capital","content":"<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Source Link</a>\n\n</div>\n","source":"lsy1603787993745","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCT","symbol_name":"Nuvectis Pharma, Inc.","start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","article_id":"1197042929","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","pubTimestamp":1644019993,"columns":[],"sourceInfo":{"source_id":"lsy1603787993745","name":"Renaissance Capital"},"weMediaInfo":null,"summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc.","TGR.AU":"Tassal Group","ACLX":"ARCELLX, INC."},"translate_title":"美国首次公开募股周报：2月首次公开募股市场以2家生物技术公司拉开序幕","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAXU":0.9,"ACLX":0.9,"BWAQU":0.9,"MURFU":0.9,"NVCT":0.9,"TGR.AU":0.9},"content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9098629116,"gmtCreate":1644117774231,"gmtModify":1676533891880,"author":{"id":"3555119187338975","authorId":"3555119187338975","name":"frusty","avatar":"https://static.tigerbbs.com/46c85297aaa1b07647be4b2ca33ea8e8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3555119187338975","authorIdStr":"3555119187338975"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098629116","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098684448,"gmtCreate":1644115636930,"gmtModify":1676533891585,"author":{"id":"3582502134655895","authorId":"3582502134655895","name":"Bspn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582502134655895","authorIdStr":"3582502134655895"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098684448","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098832698,"gmtCreate":1644075712547,"gmtModify":1676533888187,"author":{"id":"3570853427202414","authorId":"3570853427202414","name":"BKT","avatar":"https://community-static.tradeup.com/news/15cb8e8f0a7c44ca01c83b3bfdddbd86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570853427202414","authorIdStr":"3570853427202414"},"htmlText":"Good. Pls like thanks.","listText":"Good. Pls like thanks.","text":"Good. Pls like thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098832698","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098830594,"gmtCreate":1644074331993,"gmtModify":1676533888040,"author":{"id":"3575032741986642","authorId":"3575032741986642","name":"AngelAw","avatar":"https://static.tigerbbs.com/e8206a20c5dd9d81d85c5335051c8830","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575032741986642","authorIdStr":"3575032741986642"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098830594","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098379881,"gmtCreate":1644032127774,"gmtModify":1676533884541,"author":{"id":"4101003037219840","authorId":"4101003037219840","name":"cubinvestor","avatar":"https://static.tigerbbs.com/095410e2774396e121a58b9ee6557a6a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4101003037219840","authorIdStr":"4101003037219840"},"htmlText":"Great&nbsp;[Strong]&nbsp;","listText":"Great&nbsp;[Strong]&nbsp;","text":"Great [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098379881","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098348692,"gmtCreate":1644030710113,"gmtModify":1676533884362,"author":{"id":"3575588910593021","authorId":"3575588910593021","name":"Goodmeng","avatar":"https://static.tigerbbs.com/96dc060537e6112d51026eaa7dd4db92","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575588910593021","authorIdStr":"3575588910593021"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098348692","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098341958,"gmtCreate":1644030541638,"gmtModify":1676533884330,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098341958","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098352335,"gmtCreate":1644029516844,"gmtModify":1676533884148,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098352335","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098358791,"gmtCreate":1644029436141,"gmtModify":1676533883916,"author":{"id":"4088779006345160","authorId":"4088779006345160","name":"Desoupie","avatar":"https://static.tigerbbs.com/61605302726ca838436e74d61cb437ae","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4088779006345160","authorIdStr":"4088779006345160"},"htmlText":"Like pls&nbsp;[Bless]&nbsp;","listText":"Like pls&nbsp;[Bless]&nbsp;","text":"Like pls [Bless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098358791","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098358424,"gmtCreate":1644029424803,"gmtModify":1676533883916,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4101948424484190","authorIdStr":"4101948424484190"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098358424","repostId":1197042929,"repostType":2,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098350848,"gmtCreate":1644028752739,"gmtModify":1676533883817,"author":{"id":"3570811646225826","authorId":"3570811646225826","name":"pushpa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3570811646225826","authorIdStr":"3570811646225826"},"htmlText":"how &nbsp; edge <a href=\"https://ttm.financial/U/3519184485911294\">@___霞儿____</a>sxeocbshh jgbenz","listText":"how &nbsp; edge <a href=\"https://ttm.financial/U/3519184485911294\">@___霞儿____</a>sxeocbshh jgbenz","text":"how edge @___霞儿____sxeocbshh jgbenz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098350848","repostId":1197042929,"repostType":2,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098325144,"gmtCreate":1644028361863,"gmtModify":1676533883750,"author":{"id":"3572313172431959","authorId":"3572313172431959","name":"Venus888","avatar":"https://static.tigerbbs.com/2eb10c539f367e4d8f1ae8ddf081bfdf","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3572313172431959","authorIdStr":"3572313172431959"},"htmlText":"Pls like. Thanks","listText":"Pls like. Thanks","text":"Pls like. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098325144","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098326620,"gmtCreate":1644028078289,"gmtModify":1676533883716,"author":{"id":"3574521189147374","authorId":"3574521189147374","name":"ping23","avatar":"https://static.tigerbbs.com/c38fda829a130d716804cbae538a7cb8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574521189147374","authorIdStr":"3574521189147374"},"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098326620","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098364451,"gmtCreate":1644027321302,"gmtModify":1676533883527,"author":{"id":"4102455619608180","authorId":"4102455619608180","name":"haircut","avatar":"https://static.tigerbbs.com/664eac8e1f74f7555d093f964e7bab93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4102455619608180","authorIdStr":"4102455619608180"},"htmlText":"More biotech IPO?&nbsp;","listText":"More biotech IPO?&nbsp;","text":"More biotech IPO?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098364451","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098362261,"gmtCreate":1644027032067,"gmtModify":1676533883456,"author":{"id":"3571092559413416","authorId":"3571092559413416","name":"SSSG","avatar":"https://static.tigerbbs.com/8b6004ac9552e20472bc1792d3c17df6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571092559413416","authorIdStr":"3571092559413416"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098362261","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098366430,"gmtCreate":1644026949353,"gmtModify":1676533883464,"author":{"id":"3581730511233431","authorId":"3581730511233431","name":"ToTheM00N","avatar":"https://static.tigerbbs.com/7b77b689650adddd8a8560dc89fcb930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581730511233431","authorIdStr":"3581730511233431"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098366430","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098361783,"gmtCreate":1644026636251,"gmtModify":1676533883412,"author":{"id":"4088125554959510","authorId":"4088125554959510","name":"Vicholes","avatar":"https://static.itradeup.com/news/a52c68e0b84d7f61c9d9ccf225bb2bb8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088125554959510","authorIdStr":"4088125554959510"},"htmlText":"[smile]&nbsp;","listText":"[smile]&nbsp;","text":"[smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098361783","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098369815,"gmtCreate":1644026363271,"gmtModify":1676533883355,"author":{"id":"3563070726162010","authorId":"3563070726162010","name":"Jameslim29","avatar":"https://static.tigerbbs.com/753b3384fa57ecc8b7314cedcb5ed66e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3563070726162010","authorIdStr":"3563070726162010"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098369815","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098360199,"gmtCreate":1644026183864,"gmtModify":1676533883331,"author":{"id":"4102323649583470","authorId":"4102323649583470","name":"Gerinit","avatar":"https://static.tigerbbs.com/32f151d5c2b15c07d43c4d7f9f49fbab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4102323649583470","authorIdStr":"4102323649583470"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098360199","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098360060,"gmtCreate":1644026156771,"gmtModify":1676533883321,"author":{"id":"3580072870029753","authorId":"3580072870029753","name":"YauDK","avatar":"https://static.tigerbbs.com/4e00c10df4000c04392220903422d15f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580072870029753","authorIdStr":"3580072870029753"},"htmlText":"Oh ye ye&nbsp;","listText":"Oh ye ye&nbsp;","text":"Oh ye ye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098360060","repostId":1197042929,"repostType":4,"repost":{"id":"1197042929","kind":"news","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGR.AU":"Tassal Group","NVCT":"Nuvectis Pharma, Inc.","ACLX":"ARCELLX, INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":748,"commentSize":44,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}